In a previous work, we reported that passive immunization with anti-growth hormone-releasing hormone (GHRH) antibodies (GHRH-Ab) in neonatal rats caused disruption of somatotropic function that was still present 60 d posttreatment. We studied the reversibility of this condition by growth hormone (GH) replacement therapy. Neonatal rats received GHRH-Ab (50 ~U r d t , s.c.) or normal rabbit serum every second day from birth up to postnatal d 10 and received hGH (0.4 &g body weight, s.c., b i d . ) or vehicle in a 2 x 2 factorial design. Animals were studied on d 11 of age. In GHRH-Abtreated rats, GH therapy 1 ) counteracted the reduced body weight and low plasma IGF-I levels; 2) failed to modify the reduced pituitary weight and GH content; 3) further reduced the low plasma GH levels; 4) partially restored the defective GH responsiveness to GHRH; 5) failed to modify the reduced hypothalamic somatostatin and increased GHRH gene expression in the hypothalamus; and 6) reverted the decreased pituitary somatostatin binding. Morphologic and morphometric evaluation of the pituitary gland from GHRH-Ab+GH pups showed that the number of GH-labeled structures was lower than in normal rat serum-GH-treated pups, whereas the total GH immunoreact~ty per unit surface, an index of intracellular hormone concentration, was slightly higher than in vehicle-GH or GHRH-Ab pups. As determined by electron microscopy, somatotropes from GHRH-Ab+GH pups had morphologic features of high cellular activity. It appears that in GHRH-deprived pups GH replacement therapy can normalize most but not all altered indices of the somatotropic function. The effects of GH are mainly directed at the pituitaly, whereas the sensitivity of the hypothalamus to GH replacement is lower. (Pediatr Res 36: 315-322, 1994) Abbreviations GH, growth hormone GHRH, growth hormone-releasing hormone GHRH-Ab, anti-GHRH-antibodies NRS, normal rabbit serum dCTP, deoxycytidine triphosphate PRL, prolactin SS, somatostatin Recent studies by us (1,2) and by other groups (3,4) have shown that rat pups treated with GHRH-Ab may represent a suitable animal model for the study of the human growth disorders caused b y a primary hypothalamic dysfunction. Neonatal administration of GHRH-Ab permanently inhibits the growth rate and alters several indices of the hypophyseal somatotropic function (I). Received November 11, 1993: accepted March 21, 1994. Correspondence and reprint requests: Eugenio E. Muller, MD. Department of Pharmacology. Chemotherapy and Toxicology. University of Milan, via VanviIt is presently unknown whether these changes are due t o the G H R H deficiency itself o r to the consequent reduction of G H secretion. Therefore, we studied the effects of concomitant G H and GHRH-Ab treatment. W e have administered G H daily to GHRH-deprived and control pups from postnatal d 1 to 10 and subsequently evaluated in vivo and in vitro several hypothalamic and pituitary indices of somatotropic activity.
Functional Studies
Animals. Pregnant Sprague-Dawley rats (Charles River, Calco, Italy) were purchased and housed under controlled conditions (22 k TC, 65% humidity, and artificial light from 0600 to 2000 h). After birth, all litters were culled to a standard size of 12 pups and left with dams during the experimental period (see below). Studies were conducted on d 11 of age. In all, 250 pups were used.
Antiserum to GHRH. The GHRH-Ab was prepared by immunizing rabbits with a mixture of synthetic rat GHRH (5) and methylated BSA emulsified in Freund's adjuvant, as previously described (6) . The biologic efficacy of the antiserum was assessed at various levels. The GHRH-Ab has repeatedly been shown to significantly inhibit GH secretion and growth (3, 4, 7) . In addition, the antiserum was tested for rat GHRH-binding capacity with labeled rat GHRH. The antiserum dilution required to bind 30% of the tracer was approximately 1.30 000. Characterization of the antiserum showed that it was directed toward the GHRH carboxy terminal. It cross-reacted with synthetic human, bovine, and porcine GHRH by less than 4%, and the dose-response curves were not parallel with rat GHRH.
The antiserum did not cross-react with peptides that have considerable sequence homology with GHRH, including secretin, glucagon, vasoactive intestinal peptide, gastrin, motilin, bradykinin, and angiotensin.
Treatments. Each single litter was divided randomly into two groups, one of which was given GHRH-Ab (50 ~L l r a t , s.c.) starting on d 1 and then on d 2, 4, 6, 8, and 10; the other group was given equal amounts of NRS. Each group, in turn, was divided into two subgroups, which were given twice daily (at 0900 and 1900 h) hGH (Genotropin, Kabi Vitrum, Stockholm, Sweden, batch 870301, 0.4 kg/g body weight, LC.) diluted in normal saline or equal amounts of normal saline from d 1 to 10 . All experiments were performed on d 11, at 0900 h, i.e. 14 h after the last GH injection.
Eg'ct of acute GHRH. At 0830 to 0900 h, the freemoving 11-d-old rats were injected with GHRH (human GHRH-44, Sanofi, Paris, France, batch DADJOI) at the dose of 0.2 kg/kg body weight, S.C. and were killed 15 min later. Trunk blood was collected into EDTA-containing tubes. Plasma samples and anterior pituitaries were stored frozen until GH was determined by RIA, as previously described (8) . In this study, about 50 pups were used.
IGF-I MA. Plasma IGF-I concentrations were evaluated by a homologous RIA in plasma extracted with 2N HCI, 12.5%, plus 87.5% ethanol, using reagents provided by National Hormone and Pituitary Program (NHPP). The sensitivity of the assay was 100 pg/mL; intra-and interassay variabilities were less than 10%. The plasma levels of IGF-I of eight pups for each experimental group were determined.
Pituitary GHgene expression. For the evaluation of GH mRNA levels, 12 pituitaries from each experimental group were collected in pools of three samples (four pools per experimental group), immediately frozen on dry ice, and stored at -70°C until used. Total RNA was obtained by single-step acid guanidium-phenol-chloroform extraction (9) . Total RNA samples (20 pglsample) were electrophoresed on 1.2% formaldehyde-agarose gel and transferred to a nitrocellulose membrane (Schleicher & Schuell, Dassel, Germany) at room temperature for 24 h in 10 x SSC (1 x SSC = 0.1 M sodium chloridel0.01 M sodium citrate). Filters were hybridized with a rat GH cDNA sequence kindly provided by Dr. Frances DeNoto (University of California, San Francisco, CA). The probe was labeled using the Megaprime DNA labeling system (Amersham, Little Chalfont, UK) with [a-"PI~CTP to a sp act of 1 x 109 dpmlkg DNA. Control of the homogeneity of the amount of RNA loaded was performed by reprobing the filters with [ a -3 '~] d~~~-l a b e l e d P-actin cDNA. After hybridization, autoradiography was carried out at -70°C for 24 h in the presence of an intensifying screen using Hyperfil-MP (Amersham). Quantification of the hybridization signal was performed on a scanning densitometer (LKB XL Laser Densitometer, LKB, Uppsala, Sweden). Pituitary GH mRNA levels were expressed as a percentage of the control values.
Pituitary SS binding. The anterior pituitary glands of seven pups for each experimental group were excised and frozen in liquid nitrogen. The SS autoradiography was performed on 14-km-thick, slide-mounted frozen sections as described by McCarthy and Plunkett (10) . Due to the limited amount of tissue, only two concentrations of ["'I]T~~'-SS (2000 Cilmmol, Amersham) were used. One was 0.4 nM, near the receptor k,, and the other was 0.8 nM, a saturating concentration for the receptors (11). Nonspecific binding was determined with 10 pM unlabeled SS (Sigma Chemical Co., St. Louis, MO). Sections were apposed to [ 3~]~y p e r f i l m (Amersham), exposed for 3 d at -20"C, and quantified by using a computer-assisted image analyzer. The results were expressed in arbitrary densitometry units.
Hypothalamic GHRH and SS gene expression. Hypothalami of the same pups used for pituitary GH mRNA expression were collected. The ablated areas extended from the optic chiasm to the mamillary bodies and laterally to the fornix. They were collected in pools of two samples, immediately frozen on dry ice, and stored at -70°C until used. The total RNA was isolated from pooled hypothalamic tissue as alluded to previously (9) . The total RNA samples (20 pglsample) were spotted onto nitrocellulose sheets (BA 85, 0.45 km, Schleicher & Schuell; prewetted with 5 x SSC) using a slot-blot apparatus (Minifold 11, Schleicher & Schuell). Filters were hybridized with a rat GHRH cDNA (plasmid prGRF 2, kindly provided by Dr. Kelly E. Mayo, Northwestern University, Evanston, IL) and rat SS cDNA (plasmid pSR-1, kindly provided by Dr. Richard H. Goodman, Oregon Health Center, Portland, OR). Specificity of hybridization of these probes has already been tested (12, 13) . Both cDNA probes were labeled with [a-"PI~CTP as previously described for GH gene expression. Control of the homogeneity of the amount of RNA loaded was performed by reprobing the filters with [a-"PI~CTP labeled p-actin cDNA. Autoradiography was carried out at -70°C for 24-72 h with an intensifying screen (see above). Quantification of the hybridization signal was performed as previously described, and the results were expressed as the percent of the control values.
Plasma and pituitary GH. Plasma and pituitary GH content were determined in six to 10 pups for each treatment group by a double antibody RIA (14) . Results are expressed as ng/mL and pg/pituitary in terms of the National Institutes of Health standard rat GH RP-2, the potency of which was 2.0 IU/mg. The sensitivity of the assay was 0.5 ng/mL; intraassay variability was 5%. To avoid possible interassay variation, all samples of a given experiment were assayed in a single assay.
antisera are known to have negligible cross-reactivity for other hormones. The immunoreaction specificity was evaluated by either omitting the primary antiserum or preadsorbing it with 10 wg/100 FL PBS purified rat GH or PRL (UCB-Bioproducts, Brussels, Belgium) (17) .
Furthermore, on one section per animal the antiproliferating cell nuclear antigen (PCNA, BioGenex, San Ramon, CA) immunocytochemical reaction was performed to detect mitotic processes. The reaction was revealed by a biotin-streptavidin-alkaline phosphatase supersensitive detection system (BioGenex) (18) .
Thin sections (60 nm) containing the entire hemipituitary profile were then cut from postfixed and nonpostfixed blocks for the electron microscopic studies. Sections from postfixed tissue were conventionally stained for contrast by uranyl acetate and lead citrate. The immunocytochemical GH labeling was performed accord--ing to a previous protocol (16) modified as follows: no Morphologic, Morphometric, and Densitometric Studies etching, incubation in rabbit anti-human GH (Dako General. Groups and treatments were as described above for the functional study. Six rats per group were used. Under intraperitoneal ketamine hydrochloride anesthesia, whole-body perfusion-fixation was performed as previously described (15) .
Tissue processing. The brain was removed from the skull and weighed. After extraction from the basal meninges, the pituitary gland was weighed (Table 1) and cut longitudinally in half along the sagittal axis; a 0.5-mmthick frontal slice was cut from each half at the level of the maximal pituitary height to yield two standard tissue blocks per animal, one for conventional, the other for immunocytochemical studies, as previously described (16) . Tissue blocks for conventional microscopy were postfixed with 2% phosphate buffered (pH 7.4) OsO,, those for immunocytochemistry were not postfixed.
After dehydration, infiltration, and embedding in Spurr's low viscosity medium, semithin sections (1 -5 pm) were cut. Sections of each pituitary gland were stained with toluidine blue for light microscopic study. The immunocytochemical labeling of the hormones was performed by the peroxidase-antiperoxidase method, as previously described (15) . We used rabbit anti-human GH and rabbit anti-human PRL (Dako Corp., Santa Barbara, CA), both diluted 1:200. These commercially available ~o r~. ) 1 : 2 0 0 for 1 h, incubation with goat anti-rabbit IgG conjugated to 15-nm colloidal gold particles (IG; Janssen Life Science Products, Beerse, Belgium) diluted 1:40 in PBS-Tween-20 1:200, and washing in PBS-Tween-20 1:200. All thin sections were examined using a Zeiss EM-902 PC (Carl Zeiss, Zurich, Switzerland) at 80 kV.
Densitometry. Densitometry was performed using a video-based, computer-linked system programmed to identify and measure OD in the selected images. Screen displays of the amount of the immunoreactive substance in gray tones as well as the automatic measuring and evaluation of particles whose gray tone distinguished them clearly from the background were the main functions of the program. Furthermore, the interactive editing of images allowed elimination of artifacts.
The immunoreactive material in the semithin sections was quantified as previously described (19) , with modifications: the light setting was 200 lux and the images were taken by a 40x objective. In one standard frontal hemisection, the immunohistochemically labeled cytoplasmic portions of somatotrophs and lactotrophs were measured.
The following measurements were obtained: 1) number of immunocytochemically labeled anatomical structures, which roughly corresponds to the cell number; 2) total (20) . We also calculated immunoreactivity per unit area and per structure. Five windows were measured in each rat.
Statistical Analysis
In the functional studies, mean values for experimental and control groups (mean 2 SEM) were compared by t test after analysis of variance. A probability of p < 0.05 (two-tailed) was taken to indicate a significant difference among groups.
In the morphologic studies, the significance of differences among groups was calculated by the Kruskall Wallis H-test.
RESULTS
Growth rate. Until postnatal d 4, there were no differences in growth rate among experimental groups. Between postnatal d 5 and l l , GHRH-Ab-treated rats had a growth rate significantly lower than NRS-treated rats.
G H treatment increased body weight gain in NRStreated pups and prevented the reduction in growth rate induced by GHRH-Ab. In NRS+GH-treated pups, the growth-promoting effect of GH became evident starting from postnatal d 6, when their growth curve diverged significantly from that of pups given NRS alone. In GHRH-Ab-treated pups, substitutive GH therapy completely counteracted the growth inhibitory effect of GHRH-Ab, so that no difference between their body weight and that of NRS-treated pups was observed (Fig.  1) .
Pituitary weight and GH content. Both the absolute and relative (% body weight) weight of the pituitary gland were significantly reduced by GHRH-Ab treatment. Administration of GH did not modify these indices in NRSand GHRH-Ab-treated pups (Table 1) . In rats given GHRH-Ab, irrespective of concomitant GH treatment, the total pituitary GH content, but not the GH concentration (~g l m g gland), was reduced (Table 1) . Eflect of acute GHRH. Baseline plasma GH concentrations were significantly lower in GHRH-Ah-treated than in NRS-treated rats. GH treatment did not modify baseline plasma GH concentrations in NRS-treated pups but further reduced plasma GH levels in GHRH-Ah-treated pups (Table 2) .
A single dose of GHRH did not raise plasma GH concentrations in GHRH-Ah-treated pups. Administration of hGH inhibited the GH response to the GHRH challenge in NRS-treated pups but partially restored it in GHRH-Ab-treated pups (Table 2) .
Plasma IGF-I concentrations. Circulating IGF-I concentrations were lower in GHRH-Ab-treated pups than in NRS-treated ones. Administration of GH increased significantly plasma concentrations of IGF-I in NRS-treated pups and restored them to normal in GHRH-Ab-treated pups (Table 2) .
Pituitary GH gene expression. When total RNA was subjected to Northern blot hybridization, GH mRNA was detected as a single 800-bp band.
Pituitary GH mRNA levels were significantly (p < 0.01) reduced in GHRH-Ab-treated pups (-54.6 2 2.0% versus NRS-treated group). Administration of GH did not modify pituitary GH mRNA levels in GHRH-Ab-treated pups (-51.5 2 1.5% versus NRS-treated pups) (Fig. 2) .
Pituitary SS binding. SS receptor binding was significantly lower in the pituitary glands of GHRH-Ab-treated pups than in those of NRS-treated animals. Administration of GH did not modify pituitary SS binding in NRStreated pups but restored it to normal in GHRH-Ahtreated pups (Table 3) .
Hypothalamic GHRH and SS gene expression. Increased hypothalamic GHRH mRNA levels and decreased SS mRNA levels were present in GHRH-Ab-treated pups (Table 4) . Administration of GH did not modify GHRH and SS gene expression in either NRS-or GHRH-Abtreated pups (Table 4) .
Morphometry, densitometry, electron microscopy, and immunocytochemistry. The number of pituitary GH-labeled structures was lower in pups treated with GHRHAh+GH than in those given NRS+GH ( Fig. 3A and C ; Table 5 ). In contrast, the total immunoreactivity per unit surface was increased, although not significantly, in GHRH-Ab+GH-treated compared with GH-or GHRHAb-treated pups (Table 5 ). In the GHRH-Ab+GH-treated group, the immunoreactivity was confined to the cell periphery (Fig. 3C) .
The number of PRL-labeled structures was increased in GH-and GHRH-Ab+GH-treated pups, whereas the PRL immunoreactive area and the total immunoreactivity were increased only in the GHRH-Ab+GH group (Table 6) .
No cell was labeled by the antiproliferating cell nuclear antigen immunocytochemical reaction. By electron microscopy, somatotroph cells from pups treated with GHRH-Ab+GH had small and marginated granules and abundant rough endoplasmic reticulum ( Fig. 3B and D) . This finding was obtained on the conventionally postfixed preparations and confirmed by the study of comparable cells on GH-labeled thin sections.
DISCUSSION
Earlier reports suggested that GH cannot affect growth in the immediate postnatal period of several mammals (21) despite its very high concentrations in the circulation at this age period (22) (23) (24) . However, in a previous study (1) we showed that in the rat passive immunization against GHRH during the early postnatal period has profound and long-term effects on subsequent somatic growth and somatotropic function. Partial pituitary dependence of growth, even at the earliest neonatal stage, has also been evidenced more recently (25) (26) (27) . In the present study, the ability of GH replacement therapy to reverse some defective indices of somatotropic function in GHRH-deprived 10-d-old rats reinforces the view that somatic growth is pituitary dependent very early in the postnatal period.
The most overt effect of GH replacement therapy was its ability to increase body weight gain in NRS-treated rats and restore to normal the defective growth rate of GHRH-Ab-treated rats. The dose used was selected based on its capacity to restore weight gain in hypophysectomized rats (28) .
Although administration of GH also increased significantly plasma levels of IGF-I both in control and in GHRH-Ab-treated rats, the current data do not allow us to address the question of whether the growth-promoting effects of GH were mediated by the increased plasma IGF-I levels. It has been shown that, in the rat, a poor .anleA auges + q v -~~~f )
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au!les + StIN A direct effect of GH on the pituitary to inhibit its own secretion is not likely, at least in adult rats (39) . Also, the possibility that GH per se (40, 41) or through circulating or in situ IGF-I (42,43) may act at the hypothalamic level is unlikely (see below).
We have previously shown (1) and confirmed in this study that pups immunized with GHRH-Ab are completely unresponsive to exogenous GHRH immediately posttreatment. Ironically, in pups undergoing combined GHRH-Ab and GH treatment, whose GH release should be even worse than that of rats treated with GHRH-Ab alone, the GH response to GHRH was partially preserved. Some morphologic features of the somatotrophs of these pups, denoting the existence of an unexpectedly high cellular activity, support this finding. In fact, the GH immunoreactivity per unit cytoplasm area was more intense and the secretory granules were smaller in the cells of GHRH-Ab+GH-treated pups than in somatotrophs of the pups treated with GHRH-Ab or GH alone, thus indicating a higher concentration of GH molecules inside the secretory granules. The marginal location of the GH secretory granules could explain the higher GH responsiveness to GHRH, because marginated granules can be rapidly released (44) . Also, the abundant rough endoplasmic reticulum suggests an intense cytoplasmic activity, which, however, did not lead to cell proliferation, as shown by the absence of mitotic activity demonstrated with the antiproliferating cell nuclear antigen immunocytochemical reaction.
Pituitary GH-immunoreactive structures were fewer but the PRL-immunoreactive structures more numerous than in the corresponding control group. This seems to indicate 1) a particularly strong suppression of the GHRH tone, because it is known that GHRH inhibits the proliferation of mammotrophs in vitro (45) , and 2 ) a possible shift of the somatotroph population toward mammotrophs (46) . GH treatment do not allow a definite conclusion. Measurement of pituitary GHRH receptors may provide meaningful information in this context. It is noteworthy, however, that evaluation of the density of SS pituitary receptors, although confirming that GHRH-Ab treatment markedly reduced this index of somatotropic function (1) and showing that GH per se did not affect it, disclosed, most importantly, that GH treatment counteracted the inhibitory effect of GHRH-Ab. We do not know whether the protective action of GH on pituitary SS binding may account for the partial preservation of the GH-releasing action of GHRH in these pups. However, regardless of this problem, it is apparent that in GHRH-Ab-treated pups the decreased SS binding is not due to the lack of GHRH.
Administration of GH in both GHRH-Ab-treated and control rats failed to modify baseline gene expression of GHRH and SS. This finding is in contrast to our earlier study in which we observed that a 4-fold higher dose of GH, administered under the same experimental conditions, decreased hypothalamic GHRH gene expression in intact pups (34) . Consequently, it cannot be ruled out that greater GH doses or a longer treatment period may modify hypothalamic gene expression of GHRH and SS. It is noteworthy that replacement therapy with GH, at the dose presently used, did not affect significantly GHRH and SS gene expression in prepubertal hypothyroid rats (41) and that GH (75 pglrat, twice daily, s.c.) also failed to decrease the elevated GHRH mRNA levels in adult hypophysectomized rats.
In conclusion, in GHRH-deprived pups, a GH replacement therapy counteracts the disrupting effect of the passive immunization on growth rate, IGF-I production, and pituitary SS binding and improves the ability of the gland to respond to an acute GHRH challenge. GH replacement fails to revert to normal the altered gene expression of hypothalamic GHRH and SS. Thus, the action of GH early postnatally appears to be mainly directed at the pituitary, although the underlying mechan i s m (~) has yet to be clarified. 
